Francois Brisebois
Stock Analyst at Oppenheimer
(1.51)
# 3,301
Out of 5,180 analysts
74
Total ratings
31.58%
Success rate
-6.59%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $95 → $105 | $70.15 | +49.68% | 8 | Feb 25, 2026 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $4.15 | +92.77% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $5.46 | +9.89% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $31.52 | +153.81% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $4.48 | +257.14% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $2.22 | +80.18% | 1 | Jan 29, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $28.01 | +117.78% | 6 | Jan 13, 2025 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $12.62 | +121.87% | 2 | Nov 6, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $322.19 | -49.41% | 4 | Oct 31, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $18.13 | +203.36% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.17 | +8,565.51% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $6.77 | -11.37% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.94 | +274.15% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $39.72 | -64.75% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $11.82 | +449.92% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.69 | +491.72% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $16.11 | +123.46% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $2.53 | +59,305.94% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.17 | +461,438.46% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $2.04 | +440.54% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $2.29 | +686.03% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $5.53 | +804.16% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.49 | +661,124.49% | 1 | Feb 4, 2020 |
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $95 → $105
Current: $70.15
Upside: +49.68%
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $4.15
Upside: +92.77%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.46
Upside: +9.89%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $31.52
Upside: +153.81%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $4.48
Upside: +257.14%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $2.22
Upside: +80.18%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $28.01
Upside: +117.78%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $12.62
Upside: +121.87%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $322.19
Upside: -49.41%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $18.13
Upside: +203.36%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.17
Upside: +8,565.51%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $6.77
Upside: -11.37%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $2.94
Upside: +274.15%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $39.72
Upside: -64.75%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $11.82
Upside: +449.92%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.69
Upside: +491.72%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $16.11
Upside: +123.46%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $2.53
Upside: +59,305.94%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.17
Upside: +461,438.46%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $2.04
Upside: +440.54%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $2.29
Upside: +686.03%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $5.53
Upside: +804.16%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.49
Upside: +661,124.49%